GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • Final Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 6:14 PM ET

    Amgen Inc. fell $1.51 or. 9 percent, to $160.98. Biogen Idec rose $9.10 or 2.4 percent, to $383.78. Celgene Corp. fell$. 32 or. 3 percent, to $113.20.

  • April 29- Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. Amgen said on Wednesday that T-Vec was more effective in melanoma patients whose cancer had not spread to internal organs.

  • April 29- Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or "T-Vec", an engineered virus that kills cancer...

  • Midday Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 2:53 PM ET

    Amgen Inc. fell $1.39 or. 9 percent, to $161.10. Biogen Idec rose $8.25 or 2.2 percent, to $382.93. Celgene Corp. fell$. 69 or. 6 percent, to $112.83.

  • Early Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 10:45 AM ET

    Amgen Inc. rose$. 60 or. 4 percent, to $163.09. Biogen Idec rose $9.40 or 2.5 percent, to $384.08. Celgene Corp. rose$. 30 or. 3 percent, to $113.82.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Final Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 6:04 PM ET

    Amgen Inc. rose$. 11 or. 1 percent, to $162.49. Biogen Idec fell $14.59 or 3.7 percent, to $374.68. Celgene Corp. fell $1.20 or 1.0 percent, to $113.52.

  • There's a crowding out effect, "said Stanley Sun, interest rate strategist at Nomura Securities International in New York. Large corporate deals competed for investors' dollars, with Amgen and Oracle bringing out multi-part issues worth $3.5 billion and $10 billion, respectively, according to IFR, a Thomson Reuters unit. The Treasury Department sold $35...

  • Midday Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 1:50 PM ET

    Amgen Inc. rose $2.04 or 1.3 percent, to $164.42. Biogen Idec fell $8.05 or 2.1 percent, to $381.22. Celgene Corp. fell$. 81 or. 7 percent, to $113.91.

  • *U.S. to sell $35 bln 5- year notes as FOMC sets to meet. NEW YORK, April 28- U.S. "The deals are weighing on the market whether it's rate-locking or just an increase in net supply," said Sean Murphy, a Treasuries trader at Societe Generale in New York.

  • Early Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 10:39 AM ET

    Amgen Inc. fell$. 23 or. 1 percent, to $162.15. Biogen Idec fell $8.74 or 2.2 percent, to $380.53. Celgene Corp. fell $1.03 or. 9 percent, to $113.69.

  • Final Glance: Biotechnology companies Monday, 27 Apr 2015 | 6:06 PM ET

    Amgen Inc. fell $5.53 or 3.3 percent, to $162.38. Biogen Idec fell $12.44 or 3.1 percent, to $389.27. Celgene Corp. fell $4.00 or 3.4 percent, to $114.72.

  • *Amgen's fall drags downs biotech stocks. April 27- U.S. stocks ended down on Monday, led by losses in biotech shares after disappointing news from several companies including Amgen. Amgen shares led the S&P 500 and Nasdaq's decline, dropping 3.3 percent to $162.38 after U.S. regulators said Amgen's skin cancer immunotherapy cannot be considered for an...

  • *Euro gains on Greece optimism. *Gold jumps more than 2 percent. NEW YORK, April 27- Wall Street shares fell on Monday, dragged lower by biotech and healthcare stocks, while European shares and the euro advanced on optimism over talks between Greece and its lenders after Greece reshuffled its negotiating team.

  • US STOCKS-Wall St ends down as biotechs drop 4 pct Monday, 27 Apr 2015 | 4:38 PM ET

    *Amgen's fall drags downs biotech stocks. April 27- U.S. stocks ended down on Monday, led by losses in biotech shares after disappointing news from several companies including Amgen. Amgen shares led the S&P 500' s decline, dropping 3.3 percent to $162.38 after U.S. regulators said Amgen's skin cancer immunotherapy cannot be considered for an accelerated review...

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • April 27- U.S. stocks ended down on Monday, led by losses in the healthcare sector and biotech shares after disappointing news from several companies including Amgen.

  • ImmunoGen said Friday that French drugmaker Sanofi had ended a partnership on a drug called SAR3419, or coltuximab ravtansine. RBC Capital Markets analyst Simos Simeonidis said the results are big, surprising setbacks for the company because Sanofi and ImmunoGen had considered both drugs to be promising. ImmunoGen doesn't have any approved drugs of its own,...

  • *Amgen's fall drags downs biotech stocks. Amgen shares dropped 3.2 percent to $162.53 after U.S. Food and Drug Administration staff reviewers said Amgen's skin cancer immunotherapy cannot be considered for an accelerated review at this time, citing concerns over the design and results of a key study. The healthcare sector is being dragged down by reports on...

  • REUTERS BUSINESS NEW SCHEDULE AT 1830 GMT/2:30 PM ET Monday, 27 Apr 2015 | 2:38 PM ET

    Apple Inc is expected to report a 20 percent increase in quarterly profit and that iPhone sales in China surpassed those in the United States for the first time., expect by 1930 GMT/ 4:30 PM ET, by Bill Rigby, 200 words). -BARRICK GOLD-RESULTS/, expect by expect by 1930 GMT/ 4:30 PM ET, 200 words). U.S. stocks move lower as healthcare stocks led by Amgen drag on the three major...